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The ability of dendritic cells (DCs) to shape the adaptive immune response to viral infection is mediated
largely by their maturation and activation state as determined by the surface expression of HLA molecules,
costimulatory molecules, and cytokine production. Dengue is an emerging arboviral disease where the severity
of illness is influenced by the adaptive immune response to the virus. In this report, we have demonstrated that
dengue virus infects and replicates in immature human myeloid DCs. Exposure to live dengue virus led to
maturation and activation of both the infected and surrounding, uninfected DCs and stimulated production of
tumor necrosis factor alpha (TNF-a) and alpha interferon (IFN-a). Activation of the dengue virus-infected
DCs was blunted compared to the surrounding, uninfected DCs, and dengue virus infection induced low-level
release of interleukin-12 p70 (IL-12 p70), a key cytokine in the development of cell-mediated immunity (CMI).
Upon the addition of IFN-g, there was enhanced activation of dengue virus-infected DCs and enhanced dengue
virus-induced IL-12 p70 release. The data suggest a model whereby DCs are the early, primary target of dengue
virus in natural infection and the vigor of CMI is modulated by the relative presence or absence of IFN-g in
the microenvironment surrounding the virus-infected DCs. These findings are relevant to understanding the
pathogenesis of dengue hemorrhagic fever and the design of new vaccination and therapeutic strategies.
Dendritic cells (DCs) are bone marrow-derived cells that
form a system of professional antigen-presenting cells and are
an important component of the innate immune response. They
are comprised of at least three distinct subpopulations, one in
the lymphoid/plasmacytoid lineage and two in the myeloid
lineage (1, 20, 26). Myeloid DCs are found in most nonlym-
phoid organs including the epidermis (Langerhans cells), der-
mis, gastrointestinal and respiratory mucosa, and the interstitia
of vascular organs (37). Following the uptake and processing of
antigen in the periphery, immature myeloid DCs differentiate
to an activated/mature state and migrate to the T-cell-rich
areas of lymphoid organs. Activated DCs are the unique stim-
ulators of primary T-cell responses and potent stimulators of
memory responses, and they produce an array of cytokines and
chemokines (26, 44, 50, 55). Thus, DCs are critical in the
initiation of antimicrobial immunity, and they provide a crucial
step in the development of adaptive immunity.
Dengue is an emerging arboviral disease where the adaptive
immune response plays a significant role in determining the
severity of clinical illness. The dengue viruses are a group of
four antigenically related mosquito-borne flaviviruses that pro-
duce a spectrum of clinical illness and significant morbidity
throughout the tropics (30, 35). Dengue hemorrhagic fever
(DHF) and dengue shock syndrome (DSS) represent the most
severe and potentially life-threatening manifestations of a den-
gue viral infection. DHF/DSS is characterized by the rapid
onset of plasma leakage and coagulopathy near the time of
defervescence and viremia resolution. The most significant risk
factor for the development of DHF/DSS is acquisition of a
second, heterotypic dengue virus infection (3, 11, 13). During
this second dengue virus infection, it is postulated that the
preexisting, cross-reactive, adaptive immune response leads to
excessive cytokine production, complement activation, and the
release of other phlogistic factors which produce DHF/DSS.
Both the humoral and cellular components of adaptive immu-
nity have been implicated in this process (12, 40). The principal
target of dengue virus infection has been presumed to be blood
monocytes and tissue macrophages (14, 46). However, myeloid
DCs residing in the epidermis (Langerhans cells) and dermis
are the predominant cells of the innate immune system that
dengue virus encounters following the bite of an infected mos-
quito. A recent study demonstrated the permissiveness of im-
mature myeloid DCs to dengue virus infection but did not
address the effect of viral infection on the DCs (53). In this
study, we further investigated the interaction between dengue
virus and myeloid DCs. Immature myeloid DCs were gener-
ated from plastic-adherent peripheral blood mononuclear cells
(PBMC) and were considered representative of myeloid inter-
stitial DCs (1). Viral replication, DC maturation and activa-
tion, and cytokine production were examined in the hope of
understanding the factors that guide formation of antiviral
adaptive immunity, and, under certain conditions, increase the
risk of developing severe disease.
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MATERIALS AND METHODS
Generation of DCs. Immature myeloid DCs were generated from PBMC using
previously described techniques (38, 39, 44). Peripheral blood was collected in
heparinized tubes from healthy adult volunteers. PBMC were isolated on His-
topaque gradients (Sigma Chemical Co., St. Louis, Mo.), washed two times with
RPMI 1640 medium (Gibco BRL, Gaithersburg, Md.), and incubated with neur-
aminidase-treated sheep red blood cells for 1 h on ice. Erythrocyte rosette-
negative cells were collected and isolated using Histopaque gradient centrifuga-
tion. The T-cell-depleted, erythrocyte rosette-negative cells were cultured (3 3
106 cells/well) for 1 h in 24-well plates at 37°C in a CO2 incubator with RPMI
1640 and 10% heat-inactivated fetal calf serum (FCS; Gibco BRL). Nonadherent
cells were removed, and medium was replaced with the addition of human
recombinant interleukin-4 (rIL-4; 500 U/ml; Endogen Inc., Woburn, Mass.) and
human recombinant granulocyte-macrophage colony-stimulating factor (rGM-
CSF; 800 U/ml; Endogen). Fresh medium and cytokines (rIL-4 plus rGM-CSF)
were replaced every 2 to 3 days. After 7 days, the loosely adherent DCs were
collected by vigorous pipetting. The cells obtained expressed typical myeloid DC
markers, being CD32, CD142, CD162, CD202, CD562, CD401, HLA-DR1,
and CD1a1. They had an immature DC phenotype, being CD832, and com-
prised 80 to 85% of the cell population. The remaining cells were predominantly
B lymphocytes and were not infected following dengue virus exposure (data not
shown).
Dengue virus infection of DCs. Dengue type 2 virus strain 16681 (DEN-2
16681) was grown and propagated in the mosquito cell line C6/36. The titers of
virus stocks were determined by limiting dilution plaque assay on LLC-MK2 cells
(41). In some experiments, virus was inactivated by UV irradiation from a
germicidal lamp (60 min) or heat treatment (65°C for 30 min); the absence of
viable virus was confirmed by plaque assay.
Immature myeloid DCs were plated in three wells (1.5 3 106/well) and in-
fected with DEN-2 16681 at a multiplicity of infection (MOI) of 5 (two wells) or
mock infected (one well). After a 2-h incubation at 37°C in medium containing
RPMI 1640 and 5% heat-inactivated FCS, supernatant was removed and the
cells were washed twice. The DCs were then cultured in 24 well plates at 37°C in
a CO2 incubator with RPMI 1640–10% FCS–rIL-4–rGM-CSF (final volume,
1 ml). In some experiments, human recombinant gamma interferon (rIFN-g;
Endogen) was added to one well with DEN-2-infected DCs at a final concen-
tration of 100 U/ml. At 48 h, DCs were collected by vigorous pipetting and
aliquoted into tubes for fluorescence-activated cell sorting (FACS) immunostain-
ing; viable DCs were counted by trypan blue staining. Cell-free supernatants
were collected, aliquoted, and stored at 270°C. The supernatant virus titers were
determined by plaque assay on LLC-MK2 cells as previously noted. Cytokine
levels were also determined in the supernatants by enzyme-linked immunosor-
bent assay (ELISA).
The presence of contaminating lipopolysaccharide (LPS) in the culture super-
natants, media, and virus stock was assessed with the Limulus amoebocyte lysate
assay (Whittaker M. A. Bioproducts, Walkersville, Md.). Mycoplasma contami-
nation in the culture supernatants, virus stock, and C6/36 cell line was evaluated
by the Mycoplasma Rapid Detection System (Gen-Probe, San Diego, Calif.).
Antibodies for flow cytometry. The following monoclonal antibodies (MAbs)
were purchased from Pharmingen (San Diego, Calif.): fluorescein isothiocyanate
(FITC)-conjugated mouse anti-human CD3, anti-human CD14, anti-human CD20,
and isotype control (immunoglobulin G1 [IgG1]) MAbs; phycoerythrin-conju-
gated mouse anti-human HLA-DR, anti-human HLA-ABC, anti-human CD83,
anti-human CD86, anti-human CD40, anti-human CD16, anti-human CD56, and
isotype control (IgG1) MAbs; and CyChrome-conjugated mouse anti-human
CD1a MAb. Phycoerythin-conjugated mouse anti-human CD80 (IgG1) MAb
was purchased from Immunotech (Marseille, France). Mouse polyclonal anti-
DEN-2 antibody (Ab) was purified from hyperimmune mouse ascitic fluid (AF-
RIMS, Bangkok, Thailand) and directly conjugated to FITC (FITC isomer I;
Sigma).
Immunostaining and flow cytometry analysis. DCs were resuspended in stain-
ing buffer (phosphate-buffered saline, 1% heat-inactivated FCS, 0.09% sodium
azide) and aliquoted at 1.5 3 105 cells/tube. After washing twice, cells were
incubated for 30 min at 4°C with fluorescent MAbs to cell surface antigens (10
ml/tube). Cells were then fixed and permeabilized with Cytofix/Cytoperm accord-
ing to the recommendations of the manufacturer (Pharmingen). Intracellular
staining for dengue virus was accomplished by incubation with the FITC-conju-
gated anti-DEN-2 Ab (1 mg/tube) at 4°C for 30 min. After being washed twice,
cells were resuspended in 0.3 ml of staining buffer prior to FACS analysis.
Samples were analyzed using a FACScan flow cytometer (Becton Dickinson) and
the CellQuest software package. In all experiments, three-color staining was
simultaneously performed for (i) intracellular dengue virus, (ii) cell surface
expression of CD83, costimulatory molecules, or HLA antigens, and (iii) surface
CD1a expression. All analyses were performed on the CD1a1 cell population
gate; a minimum of 50,000 events was acquired.
Determination of antiflavivirus antibody. The presence of antiflavivirus anti-
body was determined in the sera of all donors. Neutralizing Ab titers to dengue
virus serotypes 1 to 4 and Japanese encephalitis virus were measured by a plaque
reduction neutralization assay (41). The 50% plaque reduction neutralization
titer was used for comparisons; a titer of .1:10 was considered evidence of prior
exposure.
ELISAs for TNF-a and IFN-a. ELISA plates (Immulon 1; Dynex Technolo-
gies, Chantilly, Va.) were coated overnight at room temperature with the appro-
priate Ab (for TNF-a, mouse anti-human TNF-a MAb 2TNF-H34A [2.0 mg/ml];
for IFN-a, sheep polyclonal anti-human IFN-a Ab [0.5 mg/ml]) (Endogen), each
at 100 ml/well. Plates were incubated with 4% bovine serum albumin (200 ml/well;
Sigma) in phosphate-buffered saline for 1 h at room temperature; 50-ml aliquots
of each sample were then added to each well. Samples were incubated at room
temperature for 1 h, and standard dilutions for the appropriate cytokines (human
rTNF-a [Endogen] and human rIFN-aA [Biosource International, Camarillo,
Calif.]) were also evaluated. All samples and standard dilutions were assayed in
duplicate. Biotinylated detecting Ab (for TNF-a, mouse anti-human TNF-a
MAb 2TNF-H33 [0.25 mg/ml]; for IFN-a, mouse anti-human IFN-a MAb 7N41
[0.75 mg/ml]) (Endogen) was added to the plate (50 ml/well) and incubated for
1 h at room temperature. This was followed by a 30-min incubation with strepta-
vidin-peroxidase (poly-HRP Streptavidin [Endogen]; 1:20,000 dilution, 100 ml/
well). Peroxidase substrate solution (Kirkegaard & Perry Laboratories Inc.,
Gaithersburg, Md.) was added, and the optical density was read in an ELISA
reader (Spectra Max 340; Molecular Devices) at a wavelength of 450 nm.
ELISA for IL-12 p70 and IL-10. IL-12 p70 and IL-10 levels in the cell-free
culture supernatants were measured using a commercial ELISA kit (Quantikine;
R&D Systems, Minneapolis, Minn.) according to the manufacturer’s instructions.
All samples and standard dilutions were assayed in duplicate.
Statistics. All values are presented as mean 6 standard error of the mean.
Statistical significance of differences after infection or treatment of groups was
calculated using the paired-samples Student t test for normally distributed vari-
ables or the Wilcoxon signed ranks test for nonparametric variables. Statistical
significance of differences between two independent groups was calculated using
the Student t test for normally distributed variables or the Mann-Whitney U test
for nonparametric variables. Correlational analysis was performed using the
Pearson statistical test. The statistical software package SPSS version 10.0 was
used for all statistical analyses.
RESULTS
Dengue virus productively infects immature myeloid DCs,
and infection is decreased the presence of IFN-g. Immature
myeloid DCs were infected with a laboratory-adapted strain of
dengue virus, DEN-2 16681, in the absence or presence of
rIFN-g. At 48 h, cells were stained for surface CD1a expression
and intracellular DEN-2 virus; the percentage of DEN-2-in-
fected CD1a1 DCs was quantitated by flow cytometry. The
intracellular location of virus in DCs was confirmed by immu-
nofluorescence microscopy; adsorption with heat-killed DEN-2
16681 or UV-inactivated virus did not result in staining with
the anti-DEN-2 Ab (data not shown). DCs were .95% viable
by trypan blue staining. In the absence of IFN-g, the percent-
age of DEN-2-infected CD1a1 DCs at 48 h was 65% 6 7%
(range, 40 to 81%), and the log10 virus titer (PFU per milliliter)
in the cell-free supernatants was 6.16 6 0.18 (range, 5.70 to
6.83) (n 5 6). The supernatant log10 virus titer (PFU per
milliliter) correlated with the percentage of DEN-2-infected
DCs (Pearson correlation coefficient 5 0.86, P 5 0.03). When
rIFN-g was added after virus adsorption, the percentage of
DEN-2-infected CD1a1 DCs at 48 h decreased to 52% 6 10%
(range, 24 to 76%) (P 5 0.02). The supernatant log10 virus titer
(PFU per milliliter) also decreased to 5.38 6 0.44 (range, 3.88
to 6.35), although this decrease did not achieve statistical sig-
nificance (P 5 0.06) (Fig. 1).
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Antibody-dependent enhancement of infection (ADE) is a
well-described in vitro phenomenon among the flaviviruses
(15, 31). Although unlikely, ADE could not be entirely ex-
cluded as a mode of infection in some experiments. All six
donors had detectable levels of neutralizing antiflavivirus Ab in
their serum (four had anti-dengue virus Ab; two had only
anti-Japanese encephalitis virus Ab). However, the level of
anti-dengue virus Ab in the donors’ sera was negatively corre-
lated with the percentage of DEN-2-infected DCs (Pearson
correlation coefficient 5 20.95, P 5 0.004). ADE of dengue
virus infection in myeloid DCs was unable to be demonstrated
in a previous study (53). The data show that dengue virus can
infect and replicate in immature myeloid DCs. IFN-g de-
creases the permissiveness of myeloid DCs to dengue virus
infection.
IFN-g enhances the activation of dengue virus-infected DCs.
DC maturation and activation is characterized by upregulation
of the costimulatory molecules CD40, CD80, CD86 (43, 44,
54), increased cell surface expression of HLA classes I and II
(43, 54), and upregulation of the specific DC marker CD83 (54,
56). Immature myeloid DCs were infected with DEN-2 16681
or DEN-2 16681 plus rIFN-g (100 U/ml) or were mock in-
fected. At 48 h, the cell surface expression of CD83, CD40, CD80,
CD86, HLA class I, and HLA class II was assessed by flow
cytometry in three groups: mock-infected (control) CD1a1
DCs (Fig. 2A), DEN-2-infected CD1a1 DCs following virus
adsorption (Fig. 2B), and uninfected (bystander) CD1a1 DCs
following virus adsorption (Fig. 2C). Significant increases in
the cell surface expression of CD83, CD40, CD80, CD86, and
HLA classes I and II were seen in the DEN-2-infected and
uninfected (bystander) DCs compared to the mock-infected
controls (Fig. 2; Table 1). In control experiments, exposure of
immature myeloid DCs to UV-inactivated dengue virus did not
induce maturation or activation as determined by CD83,
CD80, and CD86 expression (data not shown).
Mean surface levels of the mature DC marker CD83, co-
stimulatory molecules CD80/CD86, and HLA class I were sig-
nificantly lower in the DEN-2-infected DCs than in the unin-
fected (bystander) DCs. Addition of rIFN-g overcame this
suppression and increased expression of costimulatory and
HLA molecules on the cell surface of the DEN-2-infected DCs
(Table 1). Mean surface levels of CD80, CD86, and HLA class
I in the DEN-2-infected DCs with IFN-g approached or ex-
ceeded the levels seen in the uninfected (bystander) DCs with-
out IFN-g.
LPS and Mycoplasma are potent inducers of DC maturation
and activation (5, 6, 42, 52). LPS concentrations in the virus
stock and culture supernatants of the dengue virus exposed
DCs were ,5 pg/ml. The virus stock, C6/36 cell line, and DC
culture supernatants did not contain Mycoplasma, as deter-
mined by a nucleic acid hybridization assay. Thus, DC matu-
ration and activation were not due to LPS or Mycoplasma
contamination. The data demonstrate that both directly in-
fected and uninfected myeloid DCs undergo maturation and
activation after exposure to live dengue virus. The degree of
maturation and activation appears to be less in the virus in-
fected DCs than in the adjacent, uninfected DCs. Activation of
dengue virus-infected DCs can be enhanced by the addition of
IFN-g.
Dengue virus induces TNF-a and IFN-a production from
myeloid DCs. Elevated TNF-a and IFN-a levels have been de-
tected in the sera of dengue virus-infected persons. We mea-
sured dengue virus-induced production of TNF-a and IFN-a
from myeloid DCs. Immature myeloid DCs were infected with
DEN-2 16681 or mock infected. Cell-free supernatants were
collected at 48 h and assayed for TNF-a and IFN-a by ELISA.
TNF-a levels increased from 54 6 7 pg/ml in the mock-in-
fected DCs to 743 6 174 pg/ml in the dengue virus-exposed
DCs (P 5 0.01) (Fig. 3A). IFN-a levels increased from 16 6 5
U/ml in the mock-infected DCs to 101 6 17 U/ml in the
dengue virus-exposed DCs (P 5 0.009) (Fig. 3B). In control
experiments, exposure of DCs to UV-inactivated dengue virus
did not induce production of TNF-a or IFN-a (for TNF-a,
mock infection, 92 6 29 pg/ml; for UV-inactivated virus expo-
FIG. 1. Dengue virus productively infects immature myeloid DCs, and infection is decreased in the presence of IFN-g. Immature myeloid DCs
were infected with DEN-2 16681 (MOI 5 5) in the absence or presence of rIFN-g (100 U/ml). At 48 h, cells were stained for surface CD1a and
intracellular DEN-2, and cell culture supernatants were collected. (A) Percent DEN-2-infected CD1a1 DCs determined by cytofluorometry;
(B) virus titer in cell culture supernatants. The results of six independent experiments are shown. Each symbol represents one individual.
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sure, 56 6 40, n 5 2, P 5 0.2; for IFN-a, mock infection and
UV-inactivated virus exposure, ,4 U/ml, n 5 2). The data in-
dicate that replicating dengue virus induces significant TNF-a
and IFN-a release from myeloid DCs.
Dengue virus induces IL-12 p70 secretion from myeloid DCs
in the presence of IFN-g and does not induce IL-10 secretion.
Myeloid DCs have been shown to be a major source of the
IL-12 that is necessary for generation of a type 1 T-cell re-
sponse and cell-mediated immunity (CMI) (5). IL-10 is the
predominant type 2 cytokine that downregulates IL-12 produc-
tion and CMI (7). We measured dengue virus-induced produc-
tion of the biologically active heterodimer, IL-12 p70, and
IL-10 from myeloid DCs. Immature myeloid DCs were in-
fected with DEN-2 16681 or DEN-2 16681 plus rIFN-g (100
U/ml) or were mock infected. Cell-free supernatants were col-
lected at 48 h and assayed for IL-12 p70 and IL-10 by ELISA.
Production of IL-12 p70 was low following dengue virus infec-
tion. IL-12 p70 concentrations were 1.1 6 0.1 pg/ml in the
mock-infected DCs and 10.2 6 5.5 pg/ml in the dengue virus-
exposed DCs (P 5 0.2) (Fig. 4A). IL-12 p70 remained un-
changed and at the level of detection (1.0 pg/ml) following
exposure to UV-inactivated dengue virus.
In the presence of exogenous IFN-g, IL-12 p70 levels in-
creased from 4.2 6 1.0 pg/ml in the mock-infected DCs to
48.7 6 22.3 pg/ml in the dengue virus-exposed DCs, though
this did not reach statistical significance (P 5 0.07) (Fig. 4B).
FIG. 2. Dengue virus infection induces DC maturation and activation. Immature myeloid DCs were infected with DEN-2 16681 (MOI 5 5) or
mock infected. At 48 h following virus adsorption, three-color cytofluorometry of the DCs was performed. The following markers were evaluated:
(i) presence of intracellular DEN-2 virus; (ii) surface expression of CD83, CD40, CD80, CD86, HLA class I, or HLA class II; and (iii) surface
expression of CD1a. All analyses were performed on the CD1a1 cell population gate. (A) FACS profiles of mock-infected (control) CD1a1 DCs;
(B) FACS profiles of dengue virus-infected CD1a1 DCs after virus adsorption (DEN-21 gate, far right histogram); (C) FACS profiles of uninfected
(bystander) DCs after virus adsorption (DEN-22 gate, far right histogram). Open peaks, isotype control; shaded peaks, specific antibody staining.
One representative experiment of six is shown.
TABLE 1. Dengue virus infection induces DC maturation and activationa
DCs
Surface molecule expression (MFU)b
CD83
(n 5 6)
CD40
(n 5 5)
CD80
(n 5 6)
CD86
(n 5 6)
HLA class I
(n 5 6)
HLA class II
(n 5 6)
Mock infected (control) 4 6 1 1,053 6 109 49 6 9 65 6 19 23 6 3 84 6 20
Dengue virus infected 27 6 3c 1,771 6 186c 159 6 22c 508 6 105c 64 6 13c 187 6 33c
Uninfected (bystander) 46 6 6c,d 1,862 6 159c 210 6 26c,d 1,063 6 171c,d 114 6 20c,d 202 6 37c
Dengue virus infected in the presence of IFN-g (100 U/ml) 25 6 4 1,954 6 224e 240 6 23f 936 6 64f 107 6 13f 233 6 34f
a Cell surface activation marker expression in CD1a1 DCs at 48 h following dengue virus infection in the absence or presence of IFN-g.
b Expressed as specific mean fluorescence intensity units (MFU) calculated by subtracting the MFU obtained with the corresponding isotype control. Data are
presented as the mean 6 standard error of the mean.
c P # 0.01 compared to mock-infected (control) DCs.
d P # 0.01 compared to dengue virus-infected DCs.
e P 5 0.02 compared to dengue virus-infected DCs.
f P , 0.005 compared to dengue virus-infected DCs.
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The level of IL-12 p70 induced by dengue virus in the presence
of IFN-g was greater than in the absence of IFN-g (48.7 6 22.3
pg/ml and 10.2 6 5.5 pg/ml, respectively, P 5 0.03).
Dengue virus infection did not induce significant IL-10 re-
lease from immature myeloid DCs and was not affected by the
addition of IFN-g (mock-infected DCs, 37.5 6 4.5 pg/ml; den-
gue virus-exposed DCs, 42.5 6 3.8 pg/ml; dengue virus-
exposed DCs plus IFN-g [100 U/ml], 46.4 6 4.9, P 5 0.3)
(Fig. 5).
These data demonstrate that exposure of immature myeloid
DCs to live dengue virus does not induce significant IL-12 p70
production. This weak induction of IL-12 p70 secretion is not
due to increased IL-10 release. IFN-g can augment dengue
virus-induced IL-12 p70 release.
DISCUSSION
Although dengue virus infection of myeloid DCs has been
previously reported (53), this study is the first to describe the
effects of dengue virus infection on the DCs. The results of this
study provide evidence that exposure of immature myeloid
DCs to dengue virus leads to productive infection with DC
maturation and activation. Activation of the dengue virus-
infected myeloid DCs appears blunted compared to the sur-
FIG. 3. Dengue virus infection induces TNF-a and IFN-g release from myeloid DCs. Immature myeloid DCs were infected with DEN-2 16681
(MOI 5 5) or mock infected. Cell-free supernatants were collected at 48 h and assayed for TNF-a (A) and IFN-g (B) release by ELISA. The results
of six independent experiments are shown. Values are the means of duplicate determinations. Each symbol represents one individual.
FIG. 4. IFN-g enhances dengue virus-induced IL-12 p70 release from myeloid DCs. Immature myeloid DCs were infected with DEN-2 16681
(MOI 5 5) or mock infected in the presence or absence of IFN-g (100 U/ml). Cell-free supernatants were collected at 48 h and assayed for IL-12
p70 release by ELISA. (A) IL-12 p70 production in the absence of exogenous IFN-g (n 5 6); (B) IL-12 p70 production in the presence of
exogenous IFN-g (100 U/ml) (n 5 4). Values are the means of duplicate determinations. Each symbol represents one individual.
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rounding, uninfected DCs. While dengue virus infection of
myeloid DCs results in production of TNF-a and IFN-a, se-
cretion of IL-12 p70 is low. Addition of IFN-g enhances the
activation of dengue virus-infected myeloid DCs and enhances
virus-induced IL-12 p70 release.
We have demonstrated that immature human myeloid
DCs are permissive to dengue virus infection and replication,
though wide variability to infection was seen among the blood-
derived DCs from six individuals. The addition of IFN-g (100
U/ml) immediately following exposure to dengue virus en-
hanced activation of the virus-infected DCs yet decreased the
percentage of infected myeloid DCs and virus production. This
is consistent with a recent report that found immature, but not
mature or activated, myeloid DCs to be permissive to infection
with dengue virus (53). Others have also demonstrated a de-
creased permissiveness to viral infection in activated DCs but
have found the phenomenon to be stimulus dependent (4, 36).
IFN-g (100 U/ml) also decreased dengue virus replication in
human peripheral blood monocytes (48). Virus replication and
production in immature CD1a1 DCs, and their location in the
epidermis and dermis, suggest that myeloid DCs are an impor-
tant early target for dengue virus infection in vivo. Dengue
virus infection of human skin CD1a1 DCs has been recently
demonstrated ex vivo (53).
When exposed to live dengue virus, immature myeloid DCs
underwent maturation, as characterized by the upregulation of
CD83 and surface activation markers and the secretion of
cytokines. Measles virus, influenza virus, and a variety of other
microbial pathogens and products are also inducers of DC
maturation (4, 37, 45). The effects of dengue virus infection on
the maturation and activation of myeloid DCs appear to be
pleiotropic. Dengue virus infection of immature myeloid DCs
induced significant release of TNF-a and IFN-a, low levels of
IL-12 p70 release, and no appreciable IL-10 release. Whether
cytokines were produced solely by the virus-infected DCs or
additionally by the adjacent uninfected DCs could not be de-
termined; however, a productive viral infection was required.
TNF-a and IFN-a production have also been demonstrated
following dengue virus infection of human monocytes or
monocytic cell lines (18, 21). TNF-a and IFN-a can drive
maturation of both the virus-infected DCs and the adjacent
uninfected DCs, resulting in an increase in the cell surface
expression of CD83, HLA classes I and II, and costimulatory
molecules (28, 34, 44, 54). The lower mean levels of HLA class
I and CD80/CD86 on the surface of the dengue virus-infected
DCs compared to the adjacent uninfected DCs suggest that
dengue virus may exert a small inhibitory effect on the cytokine
mediated upregulation of these cell surface molecules. Flavi-
virus-induced upregulation of class I major histocompatibility
complex and CD80 expression has been previously described
(19, 27, 33, 47). Depending on the cell culture system used, this
upregulation has been found to be either cytokine dependent
(47) or cytokine independent (33). In dengue virus infection of
myeloid DCs, it appears that a cytokine-mediated effect dom-
inates the expression of HLA class I and CD80/CD86 on the
cell surface. Whether the upregulation of these T-cell stimu-
latory molecules is also counteracted by a direct viral effect will
require further study.
Dengue virus-induced IL-12 p70 release from myeloid DCs
was low but was enhanced by IFN-g. Similar findings have been
seen among other virus-exposed myeloid DCs. Adenovirus in-
fection of peripheral blood-derived myeloid DCs produced
incomplete maturation and failed to induce IL-12 p70 release
(36). IFN-a has been shown to inhibit the production of IL-12
p70 from DCs and may contribute to a suppression of IL-12
release during viral infection (29). IL-12 production from my-
eloid DCs activated by measles virus requires coculture with
lymphocytes or other CD40 ligand (CD40L)-bearing cells (8).
The engagement of CD40 on DCs by CD40L-bearing T cells
requires IFN-g in order to produce IL-12 p70 (16, 49). Thus,
for several viral pathogens, there appears to be a pattern where-
by IFN-g is an important second signal for the secretion of
bioactive IL-12 from DCs. In dengue virus-infected DCs,
IFN-g also increases expression of the molecules involved in
stimulating the antigen-specific T-cell response. This two-signal
process may represent a regulatory mechanism for modulating
potentially harmful type 1 T-cell activation early in the immune
response.
These data have relevant implications for the pathogenesis
of dengue virus-induced disease. Early in a primary infection,
dengue virus-infected DCs would be weakly activated and
would not produce significant amounts of IL-12 p70, as there is
a paucity of IFN-g and dengue virus-reactive T cells (bearing
CD40L) in the local microenvironment. With continued viral
replication and stimulation of the innate immune response,
there is eventual production of IFN-g with T- and B-cell acti-
vation. Viremia is cleared; CMI and humoral immunity de-
velop without an early, anamnestic burst of type 1 cytokines. In
this setting, the risk of proceeding to DHF/DSS is low. During
a heterotypic, second dengue virus infection, cross-reactive
memory T cells would be activated in response to dengue
virus-infected DCs. These T cells are a source of early IFN-g
and CD40L in the DC microenvironment, leading to greater
DC activation, greater T-cell stimulatory capacity, a burst of
IL-12 p70 release, increases in TNF-a (2) and IFN-g (51)
secretion, and potential dysregulation of the type 1 cytokine
response. Viremia is cleared, yet the cascade of events initiated
FIG. 5. Dengue virus infection does not induce IL-10 release from
myeloid DCs. Immature myeloid DCs were infected with DEN-2 16681
(MOI 5 5) or mock infected in the presence or absence of IFN-g (100
U/ml). Cell-free supernatants were collected at 48 h and assayed for
IL-10 release by ELISA. The results of six independent experiments
are shown. Values are the means of duplicate determinations. Each
symbol represents one individual.
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by an early, poorly controlled type 1 cytokine response likely
contributes to the pathogenesis of DHF/DSS. Plasma levels of
IFN-g, TNF-a, and soluble TNF-a receptors have been found
to be elevated in DHF/DSS compared to dengue fever (10, 17).
We have postulated that the relative presence or absence of
IFN-g in the local microenvironment surrounding dengue vi-
rus-infected DCs is a key determinant of disease manifestation
and severity. In our experiments, DCs were exposed to 100 U
of rIFN-g per ml. Although in vivo concentrations of IFN-g in
lymph nodes containing dengue virus-infected DCs are un-
known, there is evidence to suggest that 100 U/ml is within an
achievable range. Dengue virus-immune CD41 T cells have
produced 10 to 280 U of IFN-g per ml in response to dengue
virus antigens, and serum levels of IFN-g in dengue virus-
infected patients and dengue virus vaccine recipients have
reached 50 U/ml. A critical question that remains is what other
factors modulate the appearance of early IFN-g, DC activa-
tion, and IL-12 p70 production. Dengue virus-stimulated nat-
ural killer (NK) cells are a potential source of early IFN-g in
both primary and secondary infections. The percent of circu-
lating activated NK cells was found to be greater in children
who developed DHF compared to dengue fever (9). Activated
platelets may provide an alternative source of CD40L. The
number of DCs infected (viral load), differences in virus
strains, and polymorphisms in the transcriptional promoters of
IL-12 (p40 and p35) and IFN-g are potential modulators of the
early type 1 cytokine response to dengue virus infection in vivo.
The data presented here underscore the multifaceted role of
DCs in viral infection. Immature myeloid DCs are an early
target of dengue virus infection and a source of virus replica-
tion and production. At the same time, they play a critical role
in the development of both protective and pathogenic aspects
of antiviral immunity. Further studies to delineate the interac-
tion between dengue virus and DCs should provide new op-
portunities for vaccination strategies and therapeutic interven-
tions in this emerging arboviral disease.
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